Vaccine Adverse Events

Results of Com-Cov Mix-and-Match Vaccine Study

The Com-Cov2 study tested the efficacy and safety of mix-and-matching COVID-19 vaccines, including Pfizer, AstraZeneca, Moderna and Novavax. Moderna or Novavax vaccines were administered 8-12 weeks after a first dose of the Pfizer or AstraZeneca vaccine, measuring for IgG antibodies at 28 days after the second dose.

Read More »

Adenovirus Vaccines and Blood Clots

New research suggests how COVID-19 adenovirus vaccines may lead to extremely rare cases of thrombosis with thrombocytopenia syndrome (TTS), an autoimmune response which can lead to fatal blood clots. Thrombosis with thrombocytopenia was verified by the WHO as a possible adverse event to AstraZeneca and Johnson & Johnson COVID-19 vaccines earlier this year, following the first but rarely after the second dose.

Read More »

Incidence of Vaccine Adverse Events in Autoimmune Disease Patients

A comment piece published in The Lancet Rheumatology examined the results of a questionnaire assessing adverse events in those with autoimmune disease (AD) following their first COVID-19 vaccination. Participants were asked (but not obligated) to recruit a “healthy” control of similar age and sex. They were asked whether they had 1) received a COVID-19 vaccine 2) if so, whether they experienced any local or systemic adverse events in the 7 days following vaccination 3) if so, to report the severity and duration of such adverse events. Patients were also asked to monitor any changes in their autoimmune disease for up to two months post-vaccination.

Read More »